Treatment of Multiple Myeloma: Best Practices from Ochsner Health and Satellites

EP. 1: Overview on Risk Stratification in Multiple Myeloma

ByAndrew P. Dalovisio, MD,Kelly Pippin, MD,Ryan P. Griffin, MD,Thomas Atkinson, MD,Ernest C. Quintin, MD

June 9th 2023

Opening its discussion on the management of multiple myeloma, a panel of experts from Ochsner Health reviews risk stratification strategies via NCCN and mSMART guidelines.

EP. 2: Triplet Induction Therapy in Patients With Transplant-Eligible NDMM

ByAndrew P. Dalovisio, MD,Kelly Pippin, MD,Ryan P. Griffin, MD,Ernest C. Quintin, MD,Thomas Atkinson, MD

June 9th 2023

Focused discussion on the historical use of triplet regimens as induction therapy in transplant-eligible newly diagnosed multiple myeloma.

EP. 3: Quadruplet Induction Therapy in Patients With Transplant-Eligible NDMM

ByAndrew P. Dalovisio, MD,Kelly Pippin, MD,Ryan P. Griffin, MD,Ernest C. Quintin, MD,Thomas Atkinson, MD

June 16th 2023

Shared insight on the advent of quadruplet therapy regimens in the induction setting of transplant-eligible newly diagnosed multiple myeloma.

EP. 4: Transplant-Eligible NDMM: Selecting Induction Therapy Based on Risk Status

ByAndrew P. Dalovisio, MD,Kelly Pippin, MD,Ryan P. Griffin, MD,Ernest C. Quintin, MD,Thomas Atkinson, MD

June 16th 2023

In the setting of transplant-eligible newly diagnosed multiple myeloma, expert panelists consider how risk status may affect the selection of induction therapy.

EP. 5: What is the Role of Transplant in Treating Patients With NDMM?

ByAndrew P. Dalovisio, MD,Kelly Pippin, MD,Ryan P. Griffin, MD,Ernest C. Quintin, MD,Thomas Atkinson, MD

June 23rd 2023

Key opinion leaders in multiple myeloma management reflect on the current role of stem cell transplant in patients with newly diagnosed disease.

EP. 6: Determining Transplant Ineligibility in Newly Diagnosed Multiple Myeloma

ByAndrew P. Dalovisio, MD,Kelly Pippin, MD,Ryan P. Griffin, MD,Ernest C. Quintin, MD,Thomas Atkinson, MD

June 23rd 2023

Focused discussion on factors that aid in determining transplant ineligibility when a patient presents with newly diagnosed multiple myeloma.

A recent Satellite Sessions program hosted by CancerNetwork® brought together experts from different Ochsner Health campuses to discuss the diversity of practices among care providers regarding patient interactions and treatment choices.

EP. 7: Curability, Maintenance Therapy, and Unmet Needs in Multiple Myeloma

ByAndrew P. Dalovisio, MD,Ernest C. Quintin, MD,Thomas Atkinson, MD,Kelly Pippin, MD,Ryan P. Griffin, MD

June 28th 2023

A recent Satellite Sessions program hosted by CancerNetwork® brought together experts from different Ochsner Health campuses to discuss the diversity of practices among care providers regarding patient interactions and treatment choices.

EP. 8: Frontline Treatment Regimens in the Setting of Transplant-Ineligible NDMM

ByAndrew P. Dalovisio, MD,Kelly Pippin, MD,Ryan P. Griffin, MD,Ernest C. Quintin, MD,Thomas Atkinson, MD

June 30th 2023

Experts from Ochsner Health highlight treatment options for patients who present with transplant-ineligible newly diagnosed multiple myeloma.

EP. 9: Optimizing Treatment Strategies in Relapsed/Refractory Multiple Myeloma

ByAndrew P. Dalovisio, MD,Kelly Pippin, MD,Ryan P. Griffin, MD,Ernest C. Quintin, MD,Thomas Atkinson, MD

June 30th 2023

A panel of experts shares insight on treatment sequencing and selection in the setting of relapsed/refractory multiple myeloma.

EP. 10: Relapsed/Refractory Multiple Myeloma: Managing Patients on Bispecific Therapy

ByAndrew P. Dalovisio, MD,Kelly Pippin, MD,Ryan P. Griffin, MD,Ernest C. Quintin, MD,Thomas Atkinson, MD

July 7th 2023

Centering discussion on bispecific therapy, panelists consider dosing strategies and adverse event management in relapsed/refractory multiple myeloma.

EP. 11: Role of CAR T-cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

ByAndrew P. Dalovisio, MD,Kelly Pippin, MD,Ryan P. Griffin, MD,Ernest C. Quintin, MD,Thomas Atkinson, MD

July 7th 2023

Before closing out their module on relapsed/refractory multiple myeloma, key opinion leaders reflect on the role of CAR T-cell therapy and patient access to care.

EP. 12: Unmet Needs and Future Directions in the Management of Multiple Myeloma

ByAndrew P. Dalovisio, MD,Kelly Pippin, MD,Ryan P. Griffin, MD,Ernest C. Quintin, MD,Thomas Atkinson, MD

July 14th 2023

Experts from Ochsner Health close out their panel on multiple myeloma management by identifying unmet needs and sharing excitement for future evolution in the treatment landscape.

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

Achieving a “Functional Cure” With Multiple Myeloma Therapy

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)